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Background

Little is known regarding trends in poisonings
within the pediatric transgender population.
The purpose of this study was to review
medical encounters managed by bedside
medical toxicologists, and to describe
trends within the data regarding types of
exposures in this specific population.

Methods

The Toxicology Investigators Consortium
(ToxIC) database was created in 2010 by
the American College of Medical Toxicology
(ACMT) to compile data recorded by
medical toxicologists in both inpatient and
outpatient settings. In January 2017 the data
field for transgender (male-to-female,
female-to-male, or gender non-conforming)
was added to the ToxIC form. A retrospective
database review of these transgender
patient cases dating between January 2017
and December 2020 was performed.

© 2022 Lehigh Valley Health Network

Results

There were 195 transgender patients included in the
ToxIC registry between January 2017 and December
2020. Of those, 103 (52.8%) were pediatric patients
(age <18 years), 97 (49.7%) of whom were between
the ages of 13-18, and six between (3.1%) ages 7-12.
We focused on the 97 teenagers for the data
analysis. Of the 97 teenagers, 71 (73.2%) were
female-to-male, 18 (18.6%) were male-to-female,
and eight (8.2%) were gender non-conforming.
With regard to reason for the encounter, 91 (93.8%)
of the teenagers were evaluated for an intentional
pharmaceutical ingestion, compared to 73 of 92
(79.3%) of adults reporting an intentional
pharmaceutical ingestion. Four teenagers (4.1%)
reported an intentional non-pharmaceutical
ingestion—one for alcohol use, and one for an
unintentional pharmaceutical ingestion. Of
the 91 teenagers that reported an intentional
pharmaceutical ingestion, the primary agent in
24 (26.4%) cases was antidepressants, 21 (23.1%)
analgesics, 11 (12.1%) anticholinergic/antihistamines,
six (6.6%) anticonvulsants, six (6.6%) cardiovascular

medications, five (5.5%) antipsychotics, three (3.3%)
sympathomimetics, two (2.2%) cough and cold
medications, two (2.2%) opioids, and two (2.2%)
unknown pharmaceuticals. Each of the remaining
9 patients were exposed to one of the following
categories as their primary agent: anticoagulants,
antimicrobials, caustics, GI medications, herbal/
dietary supplements/vitamins, lithium, metals,
sedative-hypnotic/muscle-relaxants, and other
pharmaceuticals. The most common vital sign
abnormality in the cohort was tachycardia (HR>140),
observed in 17.5% (N=17) of the teenagers. This
compares to the 13.0% (N=12) of the 92 transgender
adults with tachycardia in the cohort. Nervous
system abnormalities were seen commonly both in
teens, 74.2% (N=72) and adults, 67.4% (N=62). The
most common nervous system abnormality was
coma/CNS depression. Of the 97 exposed teenagers,
25.8% (N=25) experienced these symptoms, and of
the 92 exposed adults, it was reported in 23.9%
(N=22). There were no deaths in either the teenage
or adult transgender groups.

Conclusion

The majority of transgender exposures
in the ToxIC registry were teenagers
ranging in age from 13-18 and the most
common reason for encounter was an
intentional pharmaceutical exposure.
The percentage of teens seen for this
reason was higher than the adult
transgender population during the
same time frame. The most common
substances ingested were antide
pressants and analgesics. Recognizing
and promoting further research on
these trends could be helpful in both
preventing and treating intentional
poisonings within the transgender
teenager population.

